A-View®, A Step Forward Within the Medical Industry.
From DeRoyal
Now available across the UK and Ireland.
Clonallon are proud to announce that we will be distributing a new innovative product, A-View®, across the UK and Ireland, brought to the market by our partners, DeRoyal.
For more information about A-View, please contact a member of our sales team: sales@clonallon.com
Video of A-View® TAVR Procedure.
An overview of A-View®
Helping to resolve the ‘blind spot’ of Transesophageal Echocardiograms.
One of the drawbacks of Transoesophageal (Oesophageal) Echocardiography (TEE) or (TOE) is that virtually all the distal ascending aorta (DAA) and aortic arch is ‘blind’ to this method as a result of the interposition of the air-filled trachea. This means that we have no real valuable information with respect to the level of atherosclerosis in this area.
A-View® Endotracheal Balloon Catheter is used to overcome the limitation of the so called ‘blind spot’ of TEE. After introduction of the saline filled catheter in the trachea, echo conduction through the trachea is enabled and the ascending aorta, aortic arch and its branching vessels can be imaged.
For more information about A-View® download the guides below.
Allows Real-Time Adjustment
A-View® Device Indications:
• Detection of Atherosclerosis
• Diagnosis of Aortic Diseases
• Monitoring Vascular and Cannula Flow
Contraindications:
May not be used in case of severe respiratory failure, tracheomalacia or contraindications for the use of TEE (e.g. systemic tissue disease affecting the esophagus and/or trachea tissue to a degree not compatible with any aspect of TEE).
30% Reduction In Mortality*
• Open Heart Procedures
• Transcatheter Heart Interventions
• Aortic Stenting
• Robotic Cardiac Surgery
• Aortic Dissection Diagnosis
* Impact of Modified Transesophageal Echocardiography on Mortality and Stroke after Cardiac Surgery: A Large Cohort Study.
Key Benefits of A-View®.
34% of the global total healthcare expenditure is spent on treating stroke patients 2. The routine use of A-View® prevents one in every 47 patients from developing a stroke3 and this produces a saving of €3,030 per patient.4
A-View® was used in 1,391 procedures. 12% of patients had to have their surgical approach modified following its use as outlined below.
The average healthcare cost of stroke per person, including in patient care, rehabilitation, follow-up care, is estimated at USD 140,048 in the United States 4.
The largest cost component of stroke was direct medical costs and indirect medical costs, accounting for 86.2% and 1.8% of the total cost respectively 4.
1 Klomp, J., 2017. Impact of Modified Transoesophageal Echocardiography on Mortality and Stroke after Cardiac Surgery: A Large Cohort Study. International Journal of Vascular Medicine,
2 Katan, M. and Luft, A., 2018. Global Health Neurology. Seminal Neurology, 38, pp.208-211.
3 Koffijerg, H., 2013. biomedcentral.com.
4 Robinson, J., Fox, K., Bullano, M. and Grandy, S., 2009. Atherosclerosis profile and incidence of cardiovascular events: a population-based survey. BMC Cardiovascular Disorders, 9(1).